Inhibition of VEGF signalling is associated with ‘normalisation’ of tumour vessels and CD8+ T cell response [63] and the combination of ICI and VEGF inhibition has become an attractive option to examine in clinical trials. The gene discussed is CD8A; the disease is neoplasm.